Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an announcement.
Shanghai Fosun Pharmaceutical announced that the proposed merger and privatisation of its subsidiary, Shanghai Henlius Biotech, was not approved by the H Shareholders’ Class Meeting, although it received approval at the Extraordinary General Meeting. As a result, Henlius will remain listed on the Main Board of the Stock Exchange. Despite the merger’s failure, Fosun Pharma maintains a controlling interest in Henlius and plans to continue supporting its biopharmaceutical R&D activities to enhance global competitiveness.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co. is a leading player in the pharmaceutical industry, focusing primarily on biopharmaceuticals and innovative research and development. The company is a key platform for antibody technology and aims to strengthen its presence in both domestic and international markets.
YTD Price Performance: -7.95%
Average Trading Volume: 1,184
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $7.83B
For an in-depth examination of 2196 stock, go to TipRanks’ Stock Analysis page.
